TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNorwegian University of Science and Technology

About this trial

TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD).

Secondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.

Eligibility criteria

Qualifiers

Breast cancer and referral for follow-up to identify potential CTRCD

Disqualifiers

Not willing or able to consent

Trial design

Treatments tested in this trial

  • Comprehensive echocardiographic follow-up
  • Simplified echocardiographic follow-up

Treatment groups

250 Participants
are divided into 2 treatment groups

Sponsors and collaborators